Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)has EPS estimate of $-1.59 for the three-month period ended2016-09-30.
The stock had EPS estimates of$-1.59 and $-1.59, respectively, for the last 7 and 30 days. The EPS estimate for the last 60 days was -1.59 and EPS estimate for the last 90 days was $-1.59. The stock’s EPS changed 0% over the last 7 days.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has seen 0 upward EPS revisions and 0 downward EPS revisions in the last 7 days. Upward EPS revisions for the last 30 and 60 days were 1 and 1, respectively. But for the last 90 and 120 days, the stock has seen 1 and 1 upward EPS revisions, respectively.
In the last 18 days, the stock has seen 1 upward EPS revisions against 1 downward revisions.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted actual EPS of $-1.35 on2016-05-09. But immediately before the announcement of the actual results, the average EPS estimate for the period ended 1 was$-1.59. The calculation of the mean EPS estimate was based on 9 EPS estimates.
In dollar terms, EPS surprised by $-0.06 per share and in percentage it surprised by -4.65%. If you work out the standard deviation of all the EPS estimates just before the reporting of the actual EPS, you end up with 0.15.
Quarterly Sales Estimates
Based on the estimates of 2 analysts covering the company, the mean annual sales estimate and the media annual sales estimates are $2.505 and $2.505, respectively. Those estimates are for the fiscal year 2016.
Of the various analyst sales estimates for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), the highest estimate is $4.49 and the lowest estimate is $0.52. If you work out the standard deviation of the sales estimates, you end up with 2.807%.
You find that the number of analysts covering Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) who increased their sales estimates in the last week was 2. On the other hand, 2 analysts who cover the stock decreased their sales estimates on it during the same period. That brings the percentage change in the mean sales estimate from the prior week to 0%.
One month ago, 2 raised their sales estimates for the stock while 2 lowered their sales estimates. As such, the mean sales estimate changed 0% compared to the prior one month.
For the three-month ago period, 2 analysts increased their sales estimates for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) while 2 narrowed their sales estimates for the stock. With that, you end up with 0% as the percentage change in the mean sales estimate from the prior three months period.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...